Cagrilintide : the amylin analogue that complements GLP-1 — Scientific guide
Cagrilintide (AM833) is a long-acting analogue of amylin, a natural satiety hormone. Studied alone and in combination with semaglutide (CagriSema), it represents a complementary pathway to GLP-1 in research on appetite control and weight loss.
What is Cagrilintide?
Cagrilintide (research code AM833) is a synthetic analog of amylin, developed by Novo Nordisk. Amylin is a 37-amino-acid peptide hormone co-secreted with insulin by the beta cells of the pancreas after meals. It acts as a satiety signal complementary to that of GLP-1.
Native amylin is unstable and difficult to use in research: it aggregates rapidly and has a very short half-life. Cagrilintide was designed to overcome these two problems thanks to an acylated structure (grafting of a fatty acid chain) that extends its half-life to several days, allowing it to be tested in weekly administration trials.
Cagrilintide is not a GLP-1 agonist. It acts on amylin and calcitonin receptors, a different signaling pathway. This is precisely what makes its combination with a GLP-1 agonist like semaglutide interesting: the two mechanisms are additive rather than overlapping.
Mechanisms of action
Cagrilintide replicates and prolongs the natural signaling of amylin through several convergent pathways.
Central satiety
It activates amylin receptors in the brainstem nuclei (area postrema) and hypothalamus, key regions for controlling food intake. This activation increases the feeling of satiety and reduces the amount of food ingested, without directly acting on the GLP-1 pathway.
Slowing of gastric emptying
Like endogenous amylin, Cagrilintide slows the rate at which food passes from the stomach to the intestine, prolonging the feeling of fullness after meals and mitigating postprandial blood sugar spikes.
Glucagon regulation
It attenuates the postprandial secretion of glucagon, the hormone that raises blood glucose, thus contributing to glucose homeostasis in addition to its effect on appetite.
Dual activity amylin / calcitonin
Cagrilintide is a dual agonist of the amylin and calcitonin receptors. This dual affinity, combined with its prolonged half-life, distinguishes it from first-generation amylin analogs such as the short-acting pramlintide.
CagriSema: association with semaglutide
The most studied research area surrounding Cagrilintide is its fixed-dose combination with semaglutide (a GLP-1 agonist), called CagriSema. The rationale is based on the complementarity of the pathways:
Cagrilintide (amylin)
- Amylin/calcitonin receptors
- Satiety via brainstem
- Gastric emptying
- Weekly Action
Semaglutide (GLP-1)
- GLP-1 Receptor
- Hypothalamic satiety
- Insulin secretion
- Weekly Action
Cagrilintide alone resulted in a 10.8% weight loss over 26 weeks in the Phase 2 trial (highest dose, compared to 3.0% with placebo), and 11.5% over 68 weeks in the cagrilintide-only group of the Phase 3 REDEFINE 1 trial. In combination with semaglutide (CagriSema), it resulted in a 20.4% weight loss over 68 weeks in the same trial. Compared to tirzepatide, CagriSema has not demonstrated at least the same level of performance (REDEFINE 4), and its application is currently under review by the FDA: see CagriSema: Trial Results and Approval.
Technical specifications of the Cagrilintide
| Property | Value |
|---|---|
| Class | Long-acting acylated amylin analogue |
| Target | Amylin and calcitonin receptors |
| Research code | AM833 |
| Molecular weight | 4,409 g/mol (C194H312N54O59S2) |
| Recommended solvent | Bacteriostatic Water USP |
| Freeze-dried preservation | Store at -20°C, away from light. |
| Reconstructed conservation | 4 weeks at +2-8°C, away from light |
Reconstitution in research
Cagrilintide is reconstituted like a conventional lyophilized peptide in bacteriostatic water. For a 5 mg vial, the addition of 1 mL of solvent yields a working concentration of 5 mg/mL. Dissolution is achieved by allowing the water to flow down the side of the vial without vigorous shaking. The solution remains stable for approximately 4 weeks at +2–8°C; repeated freeze-thaw cycles should be avoided.
Limitations and state of research
Cagrilintide is a recent molecule whose clinical development is ongoing:
- Cagrilintide alone has only been tested in phase 2 and in one group of the REDEFINE 1 trial; its phase 3 program, RENEW, started in November 2025 and has not yet published any results.
- The long-term tolerance profile of the CagriSema combination is still being characterized.
- Gastrointestinal effects (nausea, excessive satiety) are the most frequently reported, as with other satiety peptides.
- Research product: no clinical extrapolation has been validated
- Cagrilintide: the complete guide
- CagriSema: Trial results and authorization
- Cagrilintide: side effects and safety
- COA of cagrilintide: our Janoshik report
- Eloralintide (LY3841136): Eli Lilly's amylin agonist
- Retatrutide vs cagrilintide: differences, mechanisms and trials
- A Complete Guide to Peptides for Weight Loss in Experimental Research
- Semaglutide vs Retatrutide vs Tirzepatide: a scientific comparison
- Retatrutide: the triple agonist peptide in obesity research
Research cagrilintide available from MyPeptide
5 mg format, HPLC 99%+ certified with Janoshik COA. Lyophilized at -20°C. Shipped from the EU in 2 to 5 business days.
🧪 Research Peptides — Europe Delivery
≥99% purity HPLC certified by Janoshik · COA available per batch · Discreet shipping in 2 to 5 business days
🇫🇷 Retatrutide France ·
🇧🇪 Belgium ·
🇩🇪 Germany ·
🇪🇸 Spain ·
🇮🇹 Italy
🇫🇷 GHK-Cu France ·
🇧🇪 Belgium ·
🇩🇪 Germany ·
🇪🇸 Spain ·
→ All countries
📚 Scientific reference:
Lau DCW et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicenter, randomized, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. » Lancet. 2021.
PubMed PMID:34798060 →

